SWOG S1400D(NCT02965378):成纤维细胞生长因子受体抑制剂AZD4547治疗经治成纤维细胞生长因子通路激活的IV期鳞状细胞肺癌的II期研究(Lung-MAP子研究)
SWOG S1400D是Lung-MAP生物标志物驱动的II期子研究,评估FGFR抑制剂AZD4547在FGF通路激活的经治IV期鳞状细胞肺癌患者中的疗效。43例入组,27例可评估,客观缓解率7%(95%CI 0%-17%),中位无进展生存期2.7个月,中位总生存期7.5个月。AZD4547安全性可接受,但在以FGFR1/FGFR3扩增为主的队列中活性有限。
要点
- 27例可评估患者中客观缓解率7%(95%CI 0%-17%),均为部分缓解。
- 中位无进展生存期2.7个月(95%CI 1.4-4.5),中位总生存期7.5个月(95%CI 3.7-9.3)。
- 3级不良事件6例,4级脓毒症1例,安全性可接受但活性有限。
核心结论
- AZD4547安全性可接受,但在以FGFR1/FGFR3扩增为主的经治IV期鳞状细胞肺癌队列中活性有限。
- Lung-MAP中其他靶向药物的评估正在进行中。
研究设计与样本
- SWOG S1400D是Lung-MAP的生物标志物驱动治疗子研究,为II期试验。
- 入组条件为肿瘤存在FGFR改变或突变,且至少一线含铂系统治疗后进展。
- 患者口服AZD4547 80 mg每日两次。
- 主要终点为RECIST 1.1版评估的缓解,次要终点包括无进展生存期、总生存期和缓解持续时间。
- 92例被分配至S1400D,43例入组,27例接受AZD4547治疗并可评估。
主要发现
- 可评估患者中位年龄66岁(范围49-88岁),女性7例(26%),白人24例(89%)。
- FGFR改变包括FGFR1扩增23例(85%)、FGFR3扩增2例(7%)、FGFR3 S249C 2例(7%)、FGFR3融合1例(4%)。
- 27例可评估患者中,1例FGFR3 S249C患者达未确认部分缓解,缓解持续时间1.5个月;1例FGFR1扩增患者达确认部分缓解,缓解持续时间2.9个月;客观缓解率7%(95%CI 0%-17%)。
- AZD4547治疗队列中位无进展生存期2.7个月(95%CI 1.4-4.5个月),中位总生存期7.5个月(95%CI 3.7-9.3个月)。
- 3级不良事件发生于6例患者,1例患者发生4级脓毒症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with FGF pathway-activated squamous cell. This is the first phase II trial to evaluate AZD4547 as a targeted approach in patients with previously treated FGFR-altered squamous cell NSCLC and is the first demonstration of successful implementation and conduct of a national umbrella protocol in this disease setting. METHODS: Eligible patients had tumoral FGFR alteration or mutation and had progressive disease after at least one line of platinum-based systemic therapy. Patients received AZD4547 80 mg twice daily orally. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival, and duration of response (DoR). RESULTS: Ninety-two patients were assigned to S1400D, 43 were enrolled, and 27 AZD4547-treated patients were evaluable. Evaluable patients were predominantly white (n = 24, 89%), median age 66 years (range, 49-88 years old), and female (n = 7, 26%). FGFR alterations included FGFR1 amplification (n = 23; 85%), FGFR3 amplification (n = 2; 7%), FGFR3 S249C (n = 2; 7%), and FGFR3 fusion (n = 1; 4%). Treatment with ADZ4547 was well tolerated; grade 3 adverse events occurred in six patients, and one patient had grade 4 sepsis. Of 27 response-evaluable patients, 1 patient with FGFR3 S249C had unconfirmed partial response with a DoR of 1.5 months and 1 patient with FGFR1 amplification had a confirmed partial response with a DoR of 2.9 months (7%, 95% confidence interval [CI]: 0%-17%). Median progression-free survival and overall survival for the AZD4547-treated cohort were 2.7 months (95% CI: 1.4- 4.5 months) and 7.5 months (95% CI: 3.7-9.3 months). CONCLUSIONS: AZD4547 had an acceptable safety profile but minimal activity in this predominantly FGFR1/FGFR3-amplified cohort. Evaluation of other targeted agents in Lung-MAP is ongoing.
引用
- Aggarwal C, Redman MW, Lara PN, et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019. PMID: 31195180. doi:10.1016/j.jtho.2019.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。